Stay updated with breaking news from Medication Guide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ZURZUVAE™ approved as first-and-only oral treatment specifically indicated for adults with postpartum depression and on-track for planned launch in the fourth quarter of 2023 shortly after DEA...
Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45Mental health conditions are the leading cause of maternal mortality1 with PPD among the...
Key signs of active psoriatic arthritis to look out for—and conversations to have with your doctor to build a personalized treatment plan.
/PRNewswire/ -- HIKMA Pharmaceuticals, Hackensack Meridian Health (HMH) and non-profit Dispensary of Hope are teaming up to pilot a Take-Home Naloxone Program...
V940-001 is the first Phase 3 study of a planned comprehensive clinical development program being initiated following the positive primary analysis of the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial...